Financial Performance - For the three months ended December 31, 2021, the company reported revenue of HKD 20,344,000, an increase of 35% compared to HKD 15,100,000 for the same period in 2020[8] - The gross profit for the three months ended December 31, 2021, was HKD 10,036,000, representing a gross margin of 49.3%, up from HKD 8,159,000 in the same period last year[8] - The net profit attributable to the owners of the company for the three months ended December 31, 2021, was HKD 2,108,000, an increase of 3.6% from HKD 2,035,000 in the previous year[8] - For the nine months ended December 31, 2021, total revenue reached HKD 51,699,000, a 24% increase from HKD 41,244,000 in the same period of 2020[8] - The company’s total comprehensive income for the nine months ended December 31, 2021, was HKD 5,159,000, compared to HKD 4,905,000 for the same period in 2020[8] - The group reported a revenue of HKD 51,699,000 for the nine months ended December 31, 2021, compared to HKD 45,745,000 for the same period in 2020, representing an increase of approximately 12.7%[29] - Revenue from medical consumables was HKD 36,653,000 for the nine months ended December 31, 2021, slightly up from HKD 36,365,000 in the same period of 2020[29] - Revenue from medical equipment surged to HKD 11,832,000 for the nine months ended December 31, 2021, compared to HKD 6,046,000 in the same period of 2020, marking a significant increase of approximately 95.5%[29] - The group’s pre-tax profit for the nine months ended December 31, 2021, was impacted by an increase in employee costs, which rose to HKD 12,052,000 from HKD 10,198,000 in the same period of 2020[36] - The company's profit attributable to shareholders for the nine months ended December 31, 2021, decreased to approximately HKD 5,200,000 from HKD 7,700,000 for the same period in 2020, a reduction of about 32.5%[58] - Revenue increased by approximately 13.0% to about HKD 51,700,000 for the nine months ended December 31, 2021, compared to approximately HKD 45,700,000 for the same period in 2020, primarily due to increased sales of medical equipment[51] - Gross profit for the nine months ended December 31, 2021, was approximately HKD 27,200,000, an increase of about HKD 2,000,000 or 8.2% from HKD 25,200,000 for the same period in 2020[52] - The gross profit margin decreased from approximately 55.0% for the nine months ended December 31, 2020, to about 52.7% for the same period in 2021, mainly due to an increase in sales of lower-margin medical equipment[52] Expenses and Costs - Administrative and other operating expenses for the three months ended December 31, 2021, were HKD 6,751,000, an increase from HKD 5,461,000 in the same period last year[8] - Administrative and other operating expenses increased by approximately 15.0% to about HKD 19,600,000 for the nine months ended December 31, 2021, from approximately HKD 17,000,000 for the same period in 2020, primarily due to an increase in the workforce[53] - The group’s finance costs for the nine months ended December 31, 2021, included interest on lease liabilities of HKD 106,000, up from HKD 70,000 in the same period of 2020[31] - Income tax expense for the nine months ended December 31, 2021, was approximately HKD 1,300,000, compared to HKD 1,600,000 for the same period in 2020[54] Dividends and Shareholder Returns - The group did not declare an interim dividend for the nine months ended December 31, 2021, compared to HKD 3,500,000 declared for the same period in 2020[40] - The company decided not to declare an interim dividend for the nine months ended December 31, 2021, consistent with the previous year[59] Market and Business Strategy - The company continues to focus on its core business of supplying medical instruments and providing related solutions[14] - The company remains optimistic about the healthcare sector's prospects due to increasing demand for resources and solutions, an aging population, and rising healthcare awareness among the public[48] - The company plans to further diversify its product offerings and enhance customer service to improve its one-stop medical equipment solution services[48] - The company is actively seeking suitable investment opportunities to diversify its business and provide better returns to shareholders[48] - The group plans to continue focusing on expanding its market presence in Hong Kong, where all revenues are currently generated, and has no separate segment analysis due to its operational structure[24] Governance and Compliance - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards and have not been audited[20] - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2021, confirming compliance with applicable accounting standards and GEM listing rules[86] - The company has maintained compliance with all corporate governance code provisions, except for the separation of the roles of chairman and CEO[81] - The company’s board of directors has confirmed adherence to trading standards and relevant codes of conduct as of December 31, 2021[78] - The company has established independent checks to ensure the effectiveness and independence of the board despite the CEO also serving as chairman[84] - The company has a diverse board with members possessing various professional backgrounds and expertise, ensuring robust governance[84] Share Options and Securities - The company has adopted a share option scheme to incentivize selected participants, with a total of 21,460,000 options available for exercise as of December 31, 2021[74] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending December 31, 2021[77] - The company has not granted, exercised, or forfeited any share options during the nine months ending December 31, 2021[74] - As of December 31, 2021, B&A Success holds 557,424,000 shares, representing a 69.68% equity stake in the company[69] Research and Development - Research and development expenses amounted to approximately HKD 1,150,000 for the nine months ended December 31, 2021, compared to HKD 363,000 for the same period in 2020, indicating a substantial increase in investment in R&D[36] Customer Contributions - The group had a significant customer contributing HKD 6,498,000, accounting for over 10% of total revenue for the nine months ended December 31, 2021, compared to HKD 5,459,000 from a similar customer in the same period of 2020[26] No New Developments - The company has not announced any new products or technologies during this reporting period[8] - There are no significant market expansions or acquisitions reported in the current financial results[8]
君百延集团(08372) - 2022 Q3 - 季度财报